Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.64 EUR | +1.55% | -2.96% | +36.67% |
2023 | Evrofarma SA Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
2023 | Evrofarma SA Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
Valuation
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 4.512 | 8.819 | 15.93 | 13.04 | 12.44 | 9.735 |
Enterprise Value (EV) 1 | 24.35 | 26.72 | 34.41 | 31.15 | 33.5 | 29.68 |
P/E ratio | 8.42 x | 9.01 x | 101 x | 12.1 x | -35 x | 6.86 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 0.15 x | 0.27 x | 0.48 x | 0.38 x | 0.34 x | 0.21 x |
EV / Revenue | 0.79 x | 0.82 x | 1.03 x | 0.92 x | 0.91 x | 0.65 x |
EV / EBITDA | 7.36 x | 8.15 x | 9.65 x | 11 x | 20.5 x | 7.04 x |
EV / FCF | 16.5 x | 12.3 x | 20.6 x | 409 x | -13.8 x | 42.8 x |
FCF Yield | 6.06% | 8.15% | 4.86% | 0.24% | -7.27% | 2.34% |
Price to Book | 0.42 x | 0.76 x | 1.34 x | 1.01 x | 0.99 x | 0.69 x |
Nbr of stocks (in thousands) | 13,673 | 13,673 | 13,673 | 13,673 | 13,673 | 13,673 |
Reference price 2 | 0.3300 | 0.6450 | 1.165 | 0.9540 | 0.9100 | 0.7120 |
Announcement Date | 30/04/18 | 24/04/19 | 17/06/20 | 29/04/21 | 29/04/22 | 18/04/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales 1 | 30.64 | 32.54 | 33.48 | 33.91 | 36.7 | 45.38 |
EBITDA 1 | 3.306 | 3.279 | 3.565 | 2.839 | 1.634 | 4.218 |
EBIT 1 | 1.77 | 1.873 | 2.186 | 1.497 | 0.231 | 2.725 |
Operating Margin | 5.78% | 5.76% | 6.53% | 4.41% | 0.63% | 6% |
Earnings before Tax (EBT) 1 | 1.111 | 1.261 | 0.326 | 1.195 | -0.26 | 1.522 |
Net income 1 | 0.536 | 0.979 | 0.157 | 1.08 | -0.355 | 1.419 |
Net margin | 1.75% | 3.01% | 0.47% | 3.18% | -0.97% | 3.13% |
EPS 2 | 0.0392 | 0.0716 | 0.0115 | 0.0790 | -0.0260 | 0.1038 |
Free Cash Flow 1 | 1.474 | 2.177 | 1.671 | 0.0762 | -2.435 | 0.6935 |
FCF margin | 4.81% | 6.69% | 4.99% | 0.22% | -6.64% | 1.53% |
FCF Conversion (EBITDA) | 44.6% | 66.39% | 46.87% | 2.69% | - | 16.44% |
FCF Conversion (Net income) | 275.07% | 222.37% | 1,064.17% | 7.06% | - | 48.87% |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 30/04/18 | 24/04/19 | 17/06/20 | 29/04/21 | 29/04/22 | 18/04/23 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | 19.8 | 17.9 | 18.5 | 18.1 | 21.1 | 19.9 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 6 x | 5.459 x | 5.184 x | 6.378 x | 12.89 x | 4.728 x |
Free Cash Flow 1 | 1.47 | 2.18 | 1.67 | 0.08 | -2.44 | 0.69 |
ROE (net income / shareholders' equity) | 5.12% | 8.75% | 1.33% | 8.7% | -2.78% | 10.7% |
ROA (Net income/ Total Assets) | 2.49% | 2.62% | 3.2% | 2.14% | 0.31% | 3.59% |
Assets 1 | 21.52 | 37.35 | 4.909 | 50.55 | -114.2 | 39.55 |
Book Value Per Share 2 | 0.7800 | 0.8500 | 0.8700 | 0.9500 | 0.9200 | 1.030 |
Cash Flow per Share 2 | 0.0600 | 0.0400 | 0.0100 | 0.2300 | 0.0200 | 0.1100 |
Capex 1 | 0.81 | 0.82 | - | 0.9 | 3.35 | 2.05 |
Capex / Sales | 2.64% | 2.53% | - | 2.67% | 9.12% | 4.53% |
Announcement Date | 30/04/18 | 24/04/19 | 17/06/20 | 29/04/21 | 29/04/22 | 18/04/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+36.67% | 24.34M | |
+7.96% | 25.3B | |
-27.14% | 7.71B | |
-3.39% | 6.89B | |
+8.84% | 6.37B | |
+1.98% | 5.44B | |
-2.37% | 5.42B | |
+23.74% | 5.22B | |
-5.39% | 4.69B | |
+19.90% | 4.45B |
- Stock Market
- Equities
- EVROF Stock
- Financials Evrofarma SA